Pelage Pharmaceuticals advances a hair regrowth treatment toward late-stage trials
Pelage Pharmaceuticals completed a Phase 2 study and raised $120 million to support larger clinical trials of PP405, a topical gel designed to stimulate terminal hair growth.
